tbuckley/cabot-search huggingface dataset:
Grants for Scientific Research
Authors: F. Fowke
Journal: BMJ (1900)

In the Bengal Presidency during the second week of April I 3go deaths occurred from plague, including z,I68 in Patna, but exclusive of 465 in Calcutta.In the Mysore Provinces the indigenous cases of plague show a ten- dency to increase.Since the commencement of the first epidemic until April x6th, 1900, 25,81!cases of plague occurred in the Mysore Provinces, and 20,880 deaths from the disease.The numbers are all the more astonish- ing as this district has never been considered to have been afflicted by plague to so marked an extent as many other districts of India.ADEN.
Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain
Authors: Shuai Zha, Ka‐Leung Wong, Angelo H. All
Journal: Advanced Healthcare Materials (2022)

Abstract Intravenous delivery of nanomaterials containing therapeutic agents and various cargos for treating neurological disorders is often constrained by low delivery efficacy due to difficulties in passing the blood‐brain barrier (BBB). Nanoparticles (NPs) administered intranasally can move along olfactory and trigeminal nerves so that they do not need to pass through the BBB, allowing non‐invasive, direct access to selective neural pathways within the brain. Hence, intranasal (IN) administration of NPs can effectively deliver drugs and genes into targeted regions of the brain, holding potential for efficacious disease treatment in the central nervous system (CNS). In this review, current methods for delivering conjugated NPs to the brain are primarily discussed. Distinctive potential mechanisms of therapeutic nanocomposites delivered via IN pathways to the brain are then discussed. Recent progress in developing functional NPs for applications in multimodal bioimaging, drug delivery, diagnostics, and therapeutics is also reviewed. This review is then concluded by discussing existing challenges, new directions, and future perspectives in IN delivery of nanomaterials.
Bacillary and Bickettsial Infections, Acute and Chronic: A Textbook. Black Death to White Plague
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Remarks on Aphasia and Will-Making
Authors: B. Bramwell
Journal: BMJ (1897)

IN cases of aphasia important medico-legal questions, such as the ability of the patient to manage his affairs, to make a will, etc.," every now and again arise.In this lecture I propose to consider more particularly the question whether an aphasic patient is able to make a will or not.This question, which is one of the most difficult pro- blems which the medical jurist is called upon to solve, usually includes the subordinate question whether the patient is able to manage his affairs; for, speaking from a medical point of view, it seems to me that if a patient is ableto make a will he is, in most cases at all events, so far as his mental condition alone is concerned, qualified to manage his affairs, though in many cases, owing to his aphasic condition --the difficulty in communicating with the patient which the aphasic condition entails, and the paralytic condition with which the aphasia is so often associated-it will be con- venient and advisable, more especially when his affairs are complicated, that they should be managed for him.It is impossible to make any general statement regarding the will-making power of aphasic patients which will anply to all cases.Some aphasic patients are able to manage their affairs and to make a will; others are not: each case must be decided on its own merits.In reference to this point Dr. Mills, in'a valuable and sug- gestive paper, states:2 "It will be seen from this hasty glance at the scanty literature of the subject, that the medico-legal questions which may arise, in connection with the study of aphasics are somewbat numerous, although they are by no means all embraced in this review.They include many of those which the insane also present for solution, but with others especially belonging to the aphasias.At
Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions
Authors: Pedro Mendes‐Bastos, Ana Brasileiro, Pavel Kolkhir, Stefan Frischbutter, Jörg Scheffel, Sherezade Moñino‐Romero, Marcus Maurer
Journal: Allergy (2022)

Abstract Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a range of immunological pathways. The clinical application of BTK inhibitors for B‐cell malignancies has proven successful, and there is strong rationale for the potential benefits of BTK inhibitors in some autoimmune and allergic conditions, including immune‐mediated dermatological diseases. However, the established risk‐to‐benefit profile of “first‐generation” BTK inhibitors cannot be extrapolated to these emerging, non‐oncological, indications. “Next‐generation” BTK inhibitors such as remibrutinib and fenebrutinib entered clinical development for chronic spontaneous urticaria (CSU); rilzabrutinib and tirabrutinib are being studied as potential treatments for pemphigus. Promising data from early‐phase clinical trials in CSU suggest potential for these agents to achieve strong pathway inhibition, which may translate into measurable clinical benefits, as well as other effects such as the disruption of autoantibody production. BTK inhibitors may help to overcome some of the shortcomings of monoclonal antibody treatments for immune‐mediated dermatological conditions such as CSU, pemphigus, and systemic lupus erythematosus. In addition, the use of BTK inhibitors may improve understanding of the pathophysiological roles of mast cells, basophils, and B cells in such conditions.
Plasmapheresis and fulminant acute pancreatitis.
Journal: BMJ (1988)

Mean (SD) concentrations oflipids and lipoproteins in patients before and after treatment with corn oil orfish oil Patients treated with corn oil Patients treated with fish oil (n= 17) (n= 16) Before After Before AfterTotal cholesterol 6-4 (1-2) 6-2 (1-4) 6-8 (0-6) 7-0 (0 9) HDL 1-43 (047) 1-47(0-41) 1-28 (037) 1-50 (043)* HDL2 0 57 (0-36) 0-69 (0 30) 0 47 (0 23) 070 (035)** HDL3 0-85 (0 20) 0-79(0-17) 0-81(0-18) 0-79(0-14) LDL 3-99 (1-37) 3-88 (1-03) 4-3 (0-6) 4-5 (0-8) VLDL 1-02 (1-13) 0-87(095) 1 17(067) 095 (064) Triglycerides 1-5 (0-6) 1-4 (0-6) 2-2 (0 9) 1 5 (04)** *p<0-02, **p<O001.Student's t test for paired data.HDL=High density lipoprotein.LDL=Low density lipoprotein.VLDL=Very low density lipoprotein.
Annals Graphic Medicine - Bear Witness
Authors: Theresa Maatman
Journal: Annals of Internal Medicine (2020)

Web Exclusives7 July 2020Annals Graphic Medicine - Bear WitnessFREETheresa Maatman, MDTheresa Maatman, MDMedical College of Wisconsin, Milwaukee, Wisconsin (T.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0082 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Medical College of Wisconsin, Milwaukee, Wisconsin (T.M.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G19-0082.Author/Illustrator Information: Theresa Maatman, MD, is an assistant professor at the Medical College of Wisconsin. She studies the use of comics in medical education as both a content delivery mechanism and a communication tool.This article was published at Annals.org on 23 June 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 July 2020Volume 173, Issue 1Page: W10-W11KeywordsCommunication in health careConflicts of interestDisclosureHealth careMedical education ePublished: 23 June 2020 Issue Published: 7 July 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Tardive dyskinesia.
Authors: P Elmes
Journal: BMJ (1980)

dependent of the area of liposclerosis at the beginning of treatment.With leg ulcers there is some evidence' that healing follows a logarithmic curve, large ulcers healing faster than small ones.This biological phenomenon may well apply to the healing of liposclerosis; if so transformation-of the data is essential before paired comparisons are made.In the discussion the authors mention that other methods of assessing healing, such as percentage change, appeared to offer no advantages, but in what respect ?
Switching to Over-the-Counter Availability of Rescue Inhalers for Asthma
Authors: William B. Feldman, Jerry Avorn, Aaron S. Kesselheim
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inflammation
Journal: Annals of the Rheumatic Diseases (1965)

INFLAMMATIONThis journal seldom celebrates historical anniversaries.Inflammation, however, would appear to form the basis on which all rheumatology rests, and it is now just 1,900 years since Celsus (in A.D. 64) promulgated his four "cardinal signs"-rubor, dolor, tumor, and calor-to which the subsequent centuries have only managed to add a fifth, impairment of function.Just what inflammation is, what processes are involved, and what biochemical and enzymatic changes take place, remain still largely unknown.The considerable literature on inflammatory processes which are induced in different experimental animals in a variety of different ways bears,
THE LAST (?) WORD FROM CONCORD.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Officials of the Association 1982-1983
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LUNCHEON GLIMPSES OF SIR WILLIAM OSLER DURING THE WORLD WAR
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study
Authors: Yusuke Shimakawa, Pascal Veillon, Jacques Birguel, Adeline Pivert, Virginie Sauvage, Hélène Le Guillou-Guillemette, Steven Roger, Richard Njouom, Alexandra Ducancelle, Pierre Amta, Jean Marie Huraux, Jean-Pierre Adoukara, Françoise Lunel-Fabiani
Journal: The Lancet Global Health (2022)
Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).
Authors: Michiel Simon Van Der Heijden, Shilpa Gupta, Matt D. Galsky, Christina Louise Derleth, Sue Lee, Ritesh S. Kataria, Thomas Powles
Journal: Journal of Clinical Oncology (2022)

TPS589 Background: Platinum-based chemotherapy is standard first line (1L) therapy for aUC. Maintenance therapy may be offered for patients (pts) who do not progress on 1L chemotherapy. However, not all pts are eligible for maintenance therapy, with many succumbing to their disease prior to 2L. Therefore, there is a persistent unmet need for safe and effective drug combinations in the 1L setting. Enfortumab vedotin (EV) is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human mAb conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable linker. EV has previously shown an OS benefit vs chemotherapy in pts with locally advanced or metastatic urothelial carcinoma who had previously received platinum-based therapy and a PD-(L)1 inhibitor (Powles NEJM 2021). EV is FDA-approved in this and other settings (PADCEV, Seagen Inc., 2021). Preclinical studies showed that MMAE containing ADCs, including EV, induce evidence of immunogenic cell death and can enhance anti-tumor immunity, thereby laying the foundation for EV-PD-1/PD-L1 inhibitor combination (Liu Cancer Res 2020; Cao Can Res 2016). EV-302 will evaluate the efficacy and safety of EV+pembrolizumab (EV+P) combination vs gemcitabine+cisplatin (gem+cis) or carboplatin (carbo) in pts with previously untreated aUC. Methods: EV-302/KN-A39 (NCT04223856) evaluates EV+P combination vs gem+cis or carbo in previously untreated pts with aUC. Eligibility criteria include pts with measurable disease, an ECOG status of ≤2, and eligible to receive EV, P, and cis or carbo. EV+P combination includes EV (1.25 mg/kg) administration on Days 1 and 8 with P (200 mg) on Day 1. Gem+cis or carbo includes: gem (1000 mg/m 2 ) on Days 1 and 8; and cis (70 mg/m 2 ) or carbo (AUC 4.5 or 5) on Day 1 of every 3-wk cycle. Randomization is 1:1 with stratification factors: cis eligibility, PD-L1 expression, and liver metastases. The primary endpoints are PFS and OS for EV+P compared to gem+cis or carbo. Other endpoints include ORR, duration of response, disease control rate, AEs, patient reported outcomes, PK, and biomarkers. The study opened March 2020 with sites actively enrolling globally. Clinical trial information: NCT04223856.
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.
Authors: Daniel P. Petrylak, Thomas W. Flaig, Nataliya Mar, Theodore Stewart Gourdin, Sandy Srinivas, Jonathan E. Rosenberg, Maria Guseva, Yao Yu, Sujata Narayanan, Christopher J. Hoimes
Journal: Journal of Clinical Oncology (2022)

435 Background: Up to 25% of all pts diagnosed with urothelial cancer present with muscle-invasive disease for whom the risk of progression or metastasis is substantial. Neoadjuvant chemotherapy prior to radical cystectomy and pelvic lymph node dissection (RC+PLND) has been shown to prolong overall survival for patients who are cisplatin (cis) eligible. The standard of care for cis-ineligible pts undergoing surgery does not include neoadjuvant therapy. Therefore, safe, and effective neoadjuvant therapies are an unmet need for cis-ineligible pts with MIBC. Enfortumab vedotin (EV) is an antibody-drug conjugate directed to Nectin-4, which is highly expressed in urothelial cancer, and has been shown to benefit locally advanced or metastatic urothelial cancer pts in Phase II and III trials, including cis-ineligible pts. Methods: Cohort H of the EV-103 phase 1b/2 trial (NCT03288545) enrolled pts with cis-ineligible cT2-T4aN0M0 MIBC who were eligible for RC+PLND and had an ECOG of 0-2. Pts received 3 cycles of neoadjuvant EV (1.25 mg/kg) on Days 1 and 8 of every 3-week cycle prior to RC+PLND. The primary endpoint of the study was pathological complete response rate (pCRR; ypT0N0) by central review. Key secondary endpoints included pathological downstaging (pDS) rate (yp T0,Tis,Ta,T1,N0) and safety. Results from a preliminary analysis are presented. Results: 22 pts were treated. Pts had cT2 (68.2%), cT3 (27.3%), and cT4 (4.5%) tumors. 68.2% pts had predominant urothelial cancer; 31.8% had a mixed histology. 19 pts completed all 3 cycles of EV. 21 underwent RC+PLND, and 1 had a partial cystectomy. 36.4% pts had a pCR. pDS was seen in 50.0% pts, with 1 case pending central pathology review. The most common EV treatment-related adverse events (TRAEs) were fatigue (45.5%), alopecia (36.4%), and dysgeusia (36.4%). 18.2% pts had Grade ≥3 EV TRAEs. No surgeries were delayed due to EV administration. 3 pts had Grade 5 AEs while on study that were unrelated to EV; in 2 pts these AEs occurred &gt; 30 days after RC+PLND. Conclusions: Observed pCRR after neoadjuvant EV showed promising activity in cis-ineligible pts with MIBC who have a high unmet need. Adverse events were consistent with the known safety profile of EV. This first disclosure of data supports the ongoing Phase II and III programs evaluating EV in MIBC. Clinical trial information: NCT03288545.
Glandular Fever
Authors: J. F. Goodall
Journal: BMJ (1952)

POSTERIOR FOSSA infratentorial tumours in which homolateral pyramidal signs occurred and definite cerebellar signs were lacking.The practical implications of the syndrome are indicated.The association of increased intracranial pressure with mild pyramidal signs, without other localizing evidence, should lead to ventriculography rather than to angiography, unless electroencephalography shows a definite focus of delta activity in one cerebral hemisphere.
THE TREASURER'S NOTICE.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal